Insulet Corporation $PODD Shares Bought by Danske Bank A S

Key Points

• Danske Bank A S increased its stake in Insulet by 26.1% in Q4, buying an additional 9,074 shares to hold 43,829 shares worth about $12.46 million (≈0.06% of the company).
• Insider purchase: Director Michael R. Minogue bought 2,030 shares on Feb. 25 at an average price of $246.23, a ~$499,847 transaction that raised his holding to 17,483 shares (a 13.14% increase).
• Q1 beat and outlook: Insulet reported EPS of $1.55 vs. $1.48 expected and revenue of $783.8M (up 31.2% YoY); analysts’ consensus is a “Moderate Buy” with an average target of $327.24.

Danske Bank A S grew its holdings in Insulet Corporation (NASDAQ:PODD - Free Report) by 26.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 43,829 shares of the medical instruments supplier's stock after purchasing an additional 9,074 shares during the quarter. Danske Bank A S owned about 0.06% of Insulet worth $12,458,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. True Wealth Design LLC lifted its stake in Insulet by 288.0% in the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier's stock worth $30,000 after purchasing an additional 72 shares in the last quarter. Whittier Trust Co. of Nevada Inc. lifted its position in Insulet by 48.9% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier's stock worth $40,000 after buying an additional 43 shares in the last quarter. Quent Capital LLC purchased a new position in Insulet during the third quarter worth approximately $49,000. Measured Wealth Private Client Group LLC purchased a new position in Insulet during the third quarter worth approximately $49,000. Finally, Osterweis Capital Management Inc. purchased a new position in Insulet during the second quarter worth approximately $51,000.

Insider Buying and Selling

In other Insulet news, Director Michael R. Minogue bought 2,030 shares of Insulet stock in a transaction on Wednesday, February 25th. The shares were bought at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the transaction, the director directly owned 17,483 shares of the company's stock, valued at $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. 0.36% of the stock is owned by corporate insiders.

Insulet Price Performance

NASDAQ:PODD opened at $175.04 on Monday. Insulet Corporation has a 52 week low of $158.35 and a 52 week high of $354.88. The company has a quick ratio of 2.15, a current ratio of 2.81 and a debt-to-equity ratio of 0.61. The company has a market capitalization of $12.12 billion, a P/E ratio of 50.01, a P/E/G ratio of 1.03 and a beta of 1.20. The stock's fifty day moving average is $216.37 and its two-hundred day moving average is $267.14.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, beating analysts' consensus estimates of $1.48 by $0.07. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The company had revenue of $783.80 million for the quarter, compared to the consensus estimate of $768.31 million. During the same quarter in the previous year, the business earned $1.15 earnings per share. The company's revenue for the quarter was up 31.2% on a year-over-year basis. Equities analysts expect that Insulet Corporation will post 6.27 EPS for the current year.

Wall Street Analyst Weigh In

PODD has been the topic of a number of analyst reports. Raymond James Financial reduced their price objective on Insulet from $385.00 to $355.00 and set an "outperform" rating on the stock in a research report on Thursday, February 19th. Zacks Research downgraded Insulet from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 5th. TD Cowen downgraded Insulet from a "buy" rating to a "hold" rating and set a $294.00 price objective on the stock. in a research report on Monday, January 26th. Barclays reiterated an "underweight" rating and set a $286.00 price objective on shares of Insulet in a research report on Thursday, February 19th. Finally, Royal Bank Of Canada reiterated an "outperform" rating and set a $325.00 price objective on shares of Insulet in a research report on Tuesday, April 14th. Eighteen analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Insulet currently has an average rating of "Moderate Buy" and an average target price of $327.24.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.